At the moment, Herceptin is available as a subcutaneous injection but Perjeta needs to be delivered by intravenous infusion – a process that takes hours – and Roche says that means Phesgo is ...

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

Major pathological response rates were higher with Herceptin, but adding Perjeta increased toxicity without additional benefit. The trial's primary endpoint was not met, but Herceptin showed potential ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 (trastuzumab emtansine) which is sold under the brand name Kadcycla. Treatment of early ...

For Perjeta, the survival rate was 56 months versus 40 months seen with only Herceptin and chemotherapy-based treatment," said Dr Sudeep Gupta of TMC. "If patients can afford, we recommend this drug." ...

Drugs such as trastuzumab (Herceptin), pertuzumab (Perjeta), and trastuzumab deruxtecan (Enhertu) have revolutionized HER2-positive breast cancer treatment. Additionally, immune checkpoint inhibitors ...